公开(公告)号：US06662114B1

公开(公告)日：2003-12-09

申请号：US09642905

申请日：2000-08-21

申请人： Robert H. Christenson ,  Show-Hong Duh ,  Robin T. Vollmer ,  E. Magnus Ohman ,  Trevor D. Thompson ,  L. Kristin Newby ,  Robert M. Califf

发明人： Robert H. Christenson ,  Show-Hong Duh ,  Robin T. Vollmer ,  E. Magnus Ohman ,  Trevor D. Thompson ,  L. Kristin Newby ,  Robert M. Califf

IPC分类号： G01N3348

CPC分类号： C12Q1/50

摘要： A method for predicting the clinical outcome for a patient after the patient has received therapy for an acute coronary syndrome such as myocardial infarction comprises: (a) optionally, but preferably, detecting a first variable comprising a serum creatine kinase-MB release curve area in the patient after initiation of said therapy; (b) detecting a second variable comprising a serum creatine kinase-MB release curve maxima in the patient after initiation of said therapy; then (c) optionally, but preferably, detecting a third variable comprising the slope of the descending portion of the serum creatine kinase-MB release curve after initiation of said therapy (wherein a steep slope for said descending portion is a more favorable indicator of clinical outcome than a shallow slope); and (d) generating a prediction of clinical outcome for said patient from the variables collected above. The method is useful in conjunction with established therapies such as thrombolytic therapy, and is particularly useful as a surrogate end point in clinical trials of new potential therapies.

摘要翻译： 用于预测患者接受急性冠状动脉综合征如心肌梗死的治疗后患者的临床结果的方法包括：（a）任选地，但优选地，检测包含血清肌酸激酶-MB释放曲线区域的第一变量， 所述治疗开始后的患者; （b）在开始所述治疗之后检测患者中包含血清肌酸激酶-MB释放曲线最大值的第二变量; 然后（c）任选地，但优选地，检测包括在开始所述治疗之后血清肌酸激酶-MB释放曲线的下降部分的斜率的第三变量（其中所述下降部分的陡峭斜率是临床上更有利的指标 结果比浅坡）; 和（d）从上面收集的变量产生所述患者的临床结果的预测。 该方法与已有的疗法如溶栓治疗相结合，并且作为新的潜在疗法的临床试验中的替代终点是特别有用的。

公开(公告)号：US20110318726A1

公开(公告)日：2011-12-29

申请号：US13255568

申请日：2010-03-10

申请人： Svati H. Shah ,  Christopher B. Newgard ,  William E. Kraus ,  Elizabeth R. Hauser ,  Geoffrey S. Ginsburg ,  L. Kristin Newby

发明人： Svati H. Shah ,  Christopher B. Newgard ,  William E. Kraus ,  Elizabeth R. Hauser ,  Geoffrey S. Ginsburg ,  L. Kristin Newby

IPC分类号： C12Q1/00 ,  H01J49/26 ,  G01N33/64 ,  G01N33/92 ,  G01N33/68 ,  G01N33/50

CPC分类号： G01N33/6887 ,  A61B5/00 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/4866 ,  A61B5/7275 ,  G01N21/78 ,  G01N2021/7786 ,  G01N2800/324 ,  G01N2800/50 ,  G16H50/30 ,  H01J49/0027 ,  Y10T436/174614 ,  Y10T436/200833 ,  Y10T436/201666

摘要： Methods of assessing the risk of cardiovascular disease in a subject by detecting the level of at least one metabolite in a sample from the subject are disclosed herein. The level of the metabolite is indicative of the risk of cardiovascular disease in the subject. The metabolites may be acylcarnitines, amino acids, ketones, free fatty acids or hydroxybutyrate. The cardiovascular disease may be risk of a cardiovascular event, presence of coronary artery disease or risk of development of coronary artery disease.

摘要翻译： 本文公开了通过检测来自受试者的样品中至少一种代谢物的水平来评估受试者心血管疾病风险的方法。 代谢物的水平表明受试者心血管疾病的风险。 代谢物可以是酰基肉碱，氨基酸，酮类，游离脂肪酸或羟基丁酸酯。 心血管疾病可能是心血管事件，冠状动脉疾病的存在或冠状动脉疾病发展的风险。